Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

Cancer science - 1 Mar 2021

Munakata Wataru, Shirasugi Yukari, Tobinai Kensei, Onizuka Makoto, Makita Shinichi, Suzuki Rikio, Maruyama Dai, Kawai Hidetsugu, Izutsu Koji, Nakanishi Tadashi, Shiba Sari, Hojo Seichiro, Ando Kiyoshi

Abstract excerpt

BACKGROUND: Tazemetostat is a selective and orally available inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and epigenetic regulator of cellular differentiation programs. We carried out a phase I study of tazemetostat in Japanese patients with relapsed or refractory B-cell non-Hodgkin-type lymphoma (B-NHL) to evaluate its tolerability, safety, pharmacokinetics, and preliminary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biphenyl Compounds

Share to Drug Administration Schedule

Share to Enhancer of Zeste Homolog 2 Protein

Share to Lymphoma, B-Cell

Share to Morpholines

Share to Pyridones

Source

Open in PubMed Open full text

Identifiers

PMID: 33492746
DOI: 10.1111/cas.14822
PMCID: PMC7935786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.PMID 33492746Read ↗

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity Read ↗

Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.Semantic proximity Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

[INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.Semantic proximity Read ↗

Methylation alterations and advance of treatment in lymphomaSemantic proximity Read ↗

EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.Semantic proximity Read ↗

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.